PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 18):
The antibody of  claim 17 , wherein the antibody comprises:\n (a) a variable heavy chain (V H ) region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 13 and a variable light chain (V L ) region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 14, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 15-17, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 18-20; (b) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 53 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 54, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 15-17, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 18-20; (c) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 63 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 64, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 15-17, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 18-20; (d) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 73 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 74, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 15-17, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 18-20; (e) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 83 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 84, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 15-17, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 18-20; (f) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 93 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 94, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 95-97, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 98-100; (g) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 103 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 104, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 105-107, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 108-110; or (h) a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 113 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 114, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 115-117, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 118-120.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7425247585473139
- 35 USC 102 Novelty (BERT): 0.5354905168283486
- Combined Prediction Score: 0.7218213343754174
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 280.50026661237723

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test